Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial
| Autor: | Bruria Yachini, Galit Perets, Odelia Amit, Lena Atlas, Liat Shargian, Ron Ram, Moshe Yeshurun, Chen Karni, Yael Bar-On |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Surrogate endpoint Venetoclax business.industry medicine.medical_treatment Immunology Myeloid leukemia Cell Biology Hematology Hematopoietic stem cell transplantation medicine.disease Biochemistry Chemotherapy regimen Tumor lysis syndrome chemistry.chemical_compound Graft-versus-host disease chemistry Internal medicine Multicenter trial medicine business |
| Zdroj: | Blood. 134:2018-2018 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2019-126999 |
| Popis: | Introduction: Prognosis in patients with post allogeneic HCT-early relapse of AML is dismal and response to salvage treatment is less than 20%. Venetoclax has been shown to be safe and efficacious in frail/elderly patients with AML. Treatment results in an increase of pro-apoptotic function, thus the addition of alloreactive T cells may augment the anti-leukemic potency. We hypothesized that the combination of donor lymphocyte infusion may further enhance this response. Methods: Eligibility criteria for this protocol were - age>18 y, early ( Disclosures No relevant conflicts of interest to declare. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|